Buscar resultados de ensayos clínicos
Nephrogenic Fibrosing Dermopathy - 15 Studies Found
Estado | Estudiar |
Terminated |
Nombre del estudio: Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF) Condición:
|
Completed |
Nombre del estudio: Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels Condición:
|
Completed |
Nombre del estudio: Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec Condición: Nephrogenic Systemic Fibrosis Fecha: 2009-09-21 Intervenciones: Drug: Imatinib mesylate (Glivec) 400 mg, one tablet daily for 12 or 24 weeks |
Completed |
Nombre del estudio: Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis Condición: Nephrogenic Systemic Fibrosis Fecha: 2009-03-17 |
Completed |
Nombre del estudio: Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis Condición: Nephrogenic Systemic Fibrosis Fecha: 2008-05-08 Intervenciones: Drug: Imatinib mesylate 400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants dev |
Suspended |
Nombre del estudio: Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection Condición:
Fecha: 2008-12-18 |
Suspended |
Nombre del estudio: Nephrogenic Systemic Fibrosis With Gadollinum Condición:
Fecha: 2009-10-26 Intervenciones: Drug: gadollinum use of on injection gadollinum Iv for imaging |
Completed |
Nombre del estudio: Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR Condición: Nephrogenic Systemic Fibrosis Fecha: 2010-06-01 Intervenciones: Drug: Ablavar One dose of Ablavar will be administered for use during a contrast MRI examination |
Completed |
Nombre del estudio: Primovist / Eovist in Renally Impaired Patients Condición: Contrast Media Fecha: 2009-05-26 Intervenciones: Drug: Gadoxetic acid disodium (Primovist, BAY86-4873) Primovist/Eovist in approved indications at approv |
Completed |
Nombre del estudio: Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist Condición:
Fecha: 2008-08-20 Intervenciones: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882) Patients will be followed for 2 years after the |